Bat. 136, CEA-Saclay
91191 Gif-sur-Yvette cedex
FRANCE
Team Leader
Team Members
Institute Presentation
The French Alternative Energies and Atomic Energy Commission (CEA) is a government-funded technological research organisation dedicated to connecting the worlds of research and industry. As a prominent player in the European Research Area, CEA is active in four major fields: energy, defense & global security, information technologies and health technologies, associated with fundamental research of excellence, and also in the design and operation of very large research infrastructures.
The Pharmacology and Immunoanalysis Unit (SPI), headed by Dr. Christophe Junot, is part of CEA. One of its main objectives is to develop analytical chemistry tools for the detection and quantification of biomolecules in biological media. The unit has a strong expertise in mass spectrometry based metabolomics, lipidomics, glycomics, and absolute quantification of metabolites in biological media for pharmacokinetics and biomarker discovery and development. SPI has also a very long experience (more than 30 years) in producing and characterizing polyclonal and monoclonal antibodies, and also in developing specific and sensitive rapid immunoassays (ELISA, lateral flow immunoassays) for detecting proteins and pathogenic bacteria in biological media. CEA runs one of the four national nodes of MetaboHUB that is the French national facility in metabolomics and fluxomics. SPI is involved in MetaboHUB with another laboratory of CEA, the Laboratory for Data Analysis and Smart Systems (LADIS, Dr. E. Thévenot), which has strong expertise in developing innovative mathematical approaches to deal with large volume and high complexity of “omics” data (signal processing, statistical analysis, machine learning). CEA will contribute as partner in WP3 within MICROB-PREDICT by performing metabolomic and lipidomic data acquisition and processing, and by contributing to biological interpretation of such data in the frame of WP4. It will also lead WP5 in which it will develop targeted and quantitative assays using liquid chromatography coupled to mass spectrometry, and also immunoassays.